166 related articles for article (PubMed ID: 20298784)
1. Comparison of the effects of eldecalcitol and alfacalcidol on bone and calcium metabolism.
Matsumoto T; Takano T; Yamakido S; Takahashi F; Tsuji N
J Steroid Biochem Mol Biol; 2010 Jul; 121(1-2):261-4. PubMed ID: 20298784
[TBL] [Abstract][Full Text] [Related]
2. Eldecalcitol increases bone mineral density in Chinese osteoporotic patients without vitamin D or calcium supplementation.
Jiang Y; Tang H; Ma X; Cheng Q; Lin H; Jin X; Zhang Z; Yu W; He S; Kobayashi T; Uehara S; Matsumoto T; Xia W
J Bone Miner Metab; 2019 Nov; 37(6):1036-1047. PubMed ID: 31087185
[TBL] [Abstract][Full Text] [Related]
3. Eldecalcitol and calcitriol stimulates 'bone minimodeling,' focal bone formation without prior bone resorption, in rat trabecular bone.
Saito H; Takeda S; Amizuka N
J Steroid Biochem Mol Biol; 2013 Jul; 136():178-82. PubMed ID: 23069645
[TBL] [Abstract][Full Text] [Related]
4. Eldecalcitol is superior to alfacalcidol in maintaining bone mineral density in glucocorticoid-induced osteoporosis patients (e-GLORIA).
Matsumoto T; Yamamoto K; Takeuchi T; Tanaka Y; Tanaka S; Nakano T; Ito M; Tomomitsu T; Hirakawa A; Soen S
J Bone Miner Metab; 2020 Jul; 38(4):522-532. PubMed ID: 32140784
[TBL] [Abstract][Full Text] [Related]
5. Eldecalcitol improves mechanical strength of cortical bones by stimulating the periosteal bone formation in the senescence-accelerated SAM/P6 mice - a comparison with alfacalcidol.
Shiraishi A; Sakai S; Saito H; Takahashi F
J Steroid Biochem Mol Biol; 2014 Oct; 144 Pt A():119-23. PubMed ID: 24189542
[TBL] [Abstract][Full Text] [Related]
6. Eldecalcitol: a review of its use in the treatment of osteoporosis.
Sanford M; McCormack PL
Drugs; 2011 Sep; 71(13):1755-70. PubMed ID: 21902297
[TBL] [Abstract][Full Text] [Related]
7. A new active vitamin D3 analog, eldecalcitol, prevents the risk of osteoporotic fractures--a randomized, active comparator, double-blind study.
Matsumoto T; Ito M; Hayashi Y; Hirota T; Tanigawara Y; Sone T; Fukunaga M; Shiraki M; Nakamura T
Bone; 2011 Oct; 49(4):605-12. PubMed ID: 21784190
[TBL] [Abstract][Full Text] [Related]
8. Eldecalcitol: newly developed active vitamin D(3) analog for the treatment of osteoporosis.
Hagino H
Expert Opin Pharmacother; 2013 Apr; 14(6):817-25. PubMed ID: 23477453
[TBL] [Abstract][Full Text] [Related]
9. [Frontiers in vitamin D; basic research and clinical application. Eldecalcitol: the effect on bones and calcium metabolism].
Endo I; Matsumoto T
Clin Calcium; 2011 Nov; 21(11):103-10. PubMed ID: 22040826
[TBL] [Abstract][Full Text] [Related]
10. Further significant effects of eldecalcitol on bone resorption markers and bone mineral density in postmenopausal osteoporosis patients having undergone long-term bisphosphonate treatment.
Iba K; Sonoda T; Takada J; Dohke T; Yamashita T
J Bone Miner Metab; 2017 Mar; 35(2):171-176. PubMed ID: 26832388
[TBL] [Abstract][Full Text] [Related]
11. Alfacalcidol reduces accelerated bone turnover in elderly women with osteoporosis.
Shiraki M; Fukuchi M; Kiriyama T; Okamoto S; Ueno T; Sakamoto H; Nagai T
J Bone Miner Metab; 2004; 22(4):352-9. PubMed ID: 15221494
[TBL] [Abstract][Full Text] [Related]
12. Vitamin D analogs and bone: preclinical and clinical studies with eldecalcitol.
Matsumoto T; Takano T; Saito H; Takahashi F
Bonekey Rep; 2014; 3():513. PubMed ID: 24818005
[TBL] [Abstract][Full Text] [Related]
13. Daily oral 25-hydroxycholecalciferol supplementation for vitamin D deficiency in haemodialysis patients: effects on mineral metabolism and bone markers.
Jean G; Terrat JC; Vanel T; Hurot JM; Lorriaux C; Mayor B; Chazot C
Nephrol Dial Transplant; 2008 Nov; 23(11):3670-6. PubMed ID: 18579534
[TBL] [Abstract][Full Text] [Related]
14. Effects of combined treatment with eldecalcitol and alendronate on bone mass, mechanical properties, and bone histomorphometry in ovariectomized rats: a comparison with alfacalcidol and alendronate.
Sugimoto M; Futaki N; Harada M; Kaku S
Bone; 2013 Jan; 52(1):181-8. PubMed ID: 23041510
[TBL] [Abstract][Full Text] [Related]
15. Eldecalcitol normalizes bone turnover markers regardless of their pre-treatment levels.
Shiraki M; Saito H; Matsumoto T
Curr Med Res Opin; 2012 Sep; 28(9):1547-52. PubMed ID: 22794117
[TBL] [Abstract][Full Text] [Related]
16. Eldecalcitol for the treatment of osteoporosis.
Matsumoto T; Endo I
Drugs Today (Barc); 2012 Mar; 48(3):189-96. PubMed ID: 22462038
[TBL] [Abstract][Full Text] [Related]
17. Effect of phylloquinone supplementation on biochemical markers of vitamin K status and bone turnover in postmenopausal women.
Bügel S; Sørensen AD; Hels O; Kristensen M; Vermeer C; Jakobsen J; Flynn A; Mølgaard C; Cashman KD
Br J Nutr; 2007 Feb; 97(2):373-80. PubMed ID: 17298708
[TBL] [Abstract][Full Text] [Related]
18. The vitamin D analog 1α,25-Dihydroxy-2β-(3-Hydroxypropyloxy) vitamin D(3) (Eldecalcitol) is a potent regulator of calcium and phosphate metabolism.
Brown AJ; Ritter CS
Calcif Tissue Int; 2011 Nov; 89(5):372-8. PubMed ID: 21912832
[TBL] [Abstract][Full Text] [Related]
19. A new active vitamin D analog, ED-71, causes increase in bone mass with preferential effects on bone in osteoporotic patients.
Kubodera N; Tsuji N; Uchiyama Y; Endo K
J Cell Biochem; 2003 Feb; 88(2):286-9. PubMed ID: 12520528
[TBL] [Abstract][Full Text] [Related]
20. Vitamin D3 analogs for the treatment of osteoporosis.
Hagino H
Can J Physiol Pharmacol; 2015 May; 93(5):327-32. PubMed ID: 25853632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
